Top

International Urology and Nephrology

Published in:

01-07-2018 | Urology - Original Paper

Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice

Authors: Yuan Chi Shen, Hung Jen Wang, Yao Chi Chuang

Published in: International Urology and Nephrology | Issue 7/2018

Abstract

Purpose

Mirabegron is a relatively new drug to treat overactive bladder (OAB). The therapeutic doses are between 25 and 100 mg in clinical trials. We aimed to evaluate the efficacy and persistence of low-dose mirabegron (25 mg) in patients with OAB in daily urological practice.

Methods

The study was a retrospective consecutive cohort of 177 OAB patients (101 male and 76 female) treated with 25 mg of mirabegron mg since January 2016 to November 2016. The therapeutic outcomes were assessed at baseline, 4, 12, and 24 weeks.

Results

Mirabegron usage was associated with a statistically significant decrease in Overactive Bladder Symptom Score, Urgency Severity Score, urge urinary incontinence, International Prostate Symptom Score (both storage and voiding symptom) at 4-week follow-up, and the therapeutic effects were further improved at 12- and 24-week follow-up. Among them, 118 patients (66.7%) and 84 patients (47.5%) were maintained on mirabegron therapy for more than 3 and 6 months, respectively. However, 29 patients (16%) had poor response with drug discontinuation within 3 months and 8 patients (4.5%) stopped medication due to adverse effects. The overall side effect was 10.2%, and the most common side effect was elevated blood pressure (2.8%) and increased post-void residual (2.8%). Between male and female patients, there was no statistical difference of symptom improvement and drug persistence rate.

Conclusions

Low-dose mirabegron (25 mg) improves clinical outcomes in two-thirds of OAB patients with good safety profile and high persistence in daily urological practice. The therapeutic effect is similar between the genders.

Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P (2011) Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 108:1132–1138CrossRefPubMed

Wennberg AL, Molander U, Fall M, Edlund C, Peeker R, Milsom I (2009) A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Eur Urol 55:783–791CrossRefPubMed

Malmsten UG, Molander U, Peeker R, Irwin DE, Milsom I (2010) Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45-103 years. Eur Urol 58:149–156CrossRefPubMed

Kogan MI, Zachoval R, Ozyurt C, Schafer T, Christensen N (2014) Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin 30:2119–2130CrossRefPubMed

Wen JG, Li JS, Wang ZM, Huang CX, Shang XP, Su ZQ, Lu YT, Suo ZH, Wang Y, Qin GJ et al (2014) The prevalence and risk factors of OAB in middle-aged and old people in China. Neurourol Urodyn 33:387–391CrossRefPubMed

Chuang YC, Liu SP, Lee KS, Liao L, Wang J, Yoo TK, Chu R, Sumarsono B (2017) Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study. Low Urin Tract Symptoms. https://doi.org/10.1111/luts.12193 PubMedCrossRef

Brubaker L, Chapple C, Coyne KS, Kopp Z (2006) Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 68:3–8CrossRefPubMed

Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, Tannenbaum C, Wein AJ (2009) Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 19:380–394CrossRefPubMed

Oefelein MG (2011) Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 34:733–754CrossRefPubMed

10.

Wagg A, Compion G, Fahey A, Siddiqui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 110:1767–1774CrossRefPubMed

11.

Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, Yoneyama T, Nishizawa O, Andersson KE (1999) Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126:819–825CrossRefPubMedPubMedCentral

12.

Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S (1999) Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 288:1367–1373PubMed

13.

Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N (2013) Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63:296–305CrossRefPubMed

14.

Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T et al (2013) Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 63:283–295CrossRefPubMed

15.

Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K (2015) Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn 34:685–692CrossRefPubMed

16.

Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S (2013) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 189:1388–1395CrossRefPubMed

17.

Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, Boerrigter P, Drogendijk T, Ridder A, Van Der Putten-Slob I et al (2013) A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J 24:1447–1458CrossRefPubMedPubMedCentral

18.

Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stolzel M, Martin N, Gunther A, Van Kerrebroeck P (2013) A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 82:313–320CrossRefPubMed

19.

Sebastianelli A, Russo GI, Kaplan SA, McVary KT, Moncada I, Gravas S, Chapple C, Morgia G, Serni S, Gacci M (2017) Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. Int J Urol. https://doi.org/10.1111/iju.13498 PubMedCrossRef

20.

Matsukawa Y, Takai S, Funahashi Y, Yamamoto T, Gotoh M (2015) Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder. Urology 85:786–790CrossRefPubMed

21.

Vecchioli Scaldazza C, Morosetti C (2016) Comparison of therapeutic efficacy and urodynamic findings of solifenacin succinate versus mirabegron in women with overactive bladder syndrome: results of a randomized controlled study. Urol Int 97:325–329CrossRefPubMed

22.

Pindoria N, Malde S, Nowers J, Taylor C, Kelleher C, Sahai A (2017) Persistence with mirabegron therapy for overactive bladder: a real life experience. Neurourol Urodyn 36:404–408CrossRefPubMed

23.

Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A (2017) Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol 72:389–399CrossRefPubMed

24.

Sussman D, Yehoshua A, Kowalski J, Lee W, Kish J, Chaudhari S, Murray B (2017) Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract 71:3–4CrossRef

25.

Strosberg AD, Pietri-Rouxel F (1996) Function and regulation of the beta 3-adrenoceptor. Trends Pharmacol Sci 17:373–381CrossRefPubMed

26.

Chapple CR, Kaplan SA, Mitcheson D, Blauwet MB, Huang M, Siddiqui E, Khullar V (2014) Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol 21:960–967CrossRefPubMed

27.

Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE (2013) Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 67:619–632CrossRefPubMedPubMedCentral

28.

Chapple CR, Nitti VW, Khullar V, Wyndaele JJ, Herschorn S, van Kerrebroeck P, Blauwet MB, Siddiqui E (2014) Onset of action of the beta3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. World J Urol 32:1565–1572CrossRefPubMedPubMedCentral

Title: Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice
Authors: Yuan Chi Shen
Hung Jen Wang
Yao Chi Chuang
Publication date: 01-07-2018
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 7/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-018-1907-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2018

Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy?

Epidemiological characteristics of and risk factors for patients with postoperative acute kidney injury: a multicenter prospective study in 30 Chinese intensive care units

24-h urine metabolic profile: is it necessary in all kidney stone formers?

The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease

Relationship between fatigue symptoms and subjective and objective indicators in hemodialysis patients

Principles of quantitative water and electrolyte replacement of losses from osmotic diuresis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page